Article info

Download PDFPDF

Tim-3 finds its place in the cancer immunotherapy landscape

Authors

  • Nandini Acharya Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Catherine Sabatos-Peyton Exploratory Immuno-oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Ana Carrizosa Anderson Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Ana Carrizosa Anderson; acanderson{at}bwh.harvard.edu
View Full Text

Citation

Acharya N, Sabatos-Peyton C, Anderson AC
Tim-3 finds its place in the cancer immunotherapy landscape

Publication history

  • Accepted May 9, 2020
  • First published June 29, 2020.
Online issue publication 
June 29, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.